http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2139924-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
filingDate 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75ad5b2cddb0dd2e6a6771da7f23b58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99cb819332b41addfa13b8000d39c0d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5672b5fc329b347c7f79518cbe9e98d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01f8c2549fb079757fc7386c3bae13b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7de4f93d0b95bfbe5a174c683c2fd834
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_969be4285157489cd311860285f9d718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f553f950644d7e7cefdbcb93494682
publicationDate 2010-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2139924-A1
titleOfInvention Bispecific antibodies and methods for production thereof
abstract The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
priorityDate 2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66117
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128871932
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226474347
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18179261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135808554
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID745
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136210299
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID81462
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65181
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87392441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226590102
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124886
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129362157
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228576085
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127378856
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400160
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6058
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128145277
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87082812
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394609
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5884
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427900

Total number of triples: 61.